March 16 (Reuters) - BioMarin Pharmaceutical will discontinue mid-stage trials of its bone disorder treatment after reports of several cases of patients' hip joint slipping out of place, the drugmaker ...
ZME Science on MSN
A hidden bone receptor could open the door to reversing osteoporosis
Osteoporosis is a common disorder in which bones lose density and become more fragile. Over time, that raises the risk of ...
Miami University researchers are developing a design tool that will be made freely available to scientists, educators, and ...
Bone health during breast cancer treatment can be a concern, but there are ways to reduce the impact. If a person is at risk for a loss of bone density, doctors can prescribe medications. Lifestyle ...
On December 22nd of 2023, a Vietnamese patient underwent hours-long surgery in order to remove part of his pelvis and femur, as per the usual treatment for bone cancer. What was special here was that ...
Novosteo Inc. will use funding to advance development of NOV004 for the treatment of bone fractures, other bone diseases and support Phase 1 clinical trials. WEST LAFAYETTE, Ind. – Novosteo Inc., a ...
Please provide your email address to receive an email when new articles are posted on . To help individuals who undergo cancer treatment lead healthier lives, Stacyann Bailey, PhD, has one overarching ...
Bone cancer is an uncommon type that can occur when cells in the bones begin to grow at an uncontrollable rate. It may happen in any bone, including those in the feet. However, it most commonly ...
Read full article: Why are prenatal and postnatal care so important? An OB-GYN explains. Blood cancer is one of the most dangerous in the world, but advancements in treatment are changing to landscape ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results